Abstract
Abstract Aims In the era of personalized therapy liquid biopsy is
considered an important diagnostic tool in the clinical management of
cancer patients. Tissue specimen represents “gold standard” for
molecular evaluation of specific gene targets alterations that lead
cancer patients to benefit of a “tailed therapy” based on molecular
features of the tumor. This innovative source of nucleic acids was
introduced in clinical setting only for NSCLC patients to test Epidermal
Grow Factor Receptor (EGFR) mutations when tissue is not available or to
monitor acquired resistance mutation after a first line of treatment.
The study aimed at assessing the diagnostic potential of liquid biopsy
in balanced tertiary screening modeling. Methods From 2014 to 2019
molecular diagnostics activity performed on liquid biopsy specimens in
the Predictive Diagnostic laboratory of AOU Federico II were reviewed.
Laboratory data were collected in SPSS. Non parametric analysis were
performed in order to test the differences between patients WILD TYPE or
not. A multivariate logistic model was performed in order to assess the
effect of mutation, age and sex, on the tumor progression. The results
of the revision concern 515 total cases (almost of all plasma or
peripheral blood) allowed to evaluate the liquid biopsies for women and
men. The average age of the Patients is 66.3 years, and the 25
percentile is 59 years. Results The cases are 221 basal and 294 by
progression after first line TKIs treatment. The cases with mutation, as
expected, have an OR 4,15 compared to the basal to have a tumor
progression (95% IC: 2,7 - 6,3) regardless of sex and age. The
mutations detected were 131 from different types of lung
carcinomas.Conclusions Working on case data, specifying the
characteristics of the Patients with mutations will drive a further
estimate in tertiary prevention screening designs